Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout
Sanofi is scrapping trials for an eczema drug derived from its billion-dollar acquisition of Kymab following a pipeline review.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Sanofi has decided to abandon plans to seek approval for amlitelimab, an OX40L antibody used to treat atopic dermatitis. This drug originated from the company's acquisition of Kymab, a deal valued between $1.1 billion and $1.4 billion.
Coverage from the Wall Street Journal, BioSpace, and Fierce Biotech emphasizes that the decision follows a review of the company's pipeline under a new CEO. Endpoints News and FirstWord Pharma further specify that the amlitelimab trials have been scrapped or shelved.
Future developments will depend on the results of the ongoing pipeline review conducted by Sanofi's new leadership.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 29m ago.
Quick answers
What drug is Sanofi abandoning?
Sanofi is shelving amlitelimab, an OX40L antibody intended for atopic dermatitis (eczema).
How much did Sanofi pay for Kymab?
Coverage lists the Kymab buyout value as $1.1 billion in one report and $1.4 billion in another.
Why was the drug dropped?
The decision occurred amid a review of Sanofi's pipeline under its new CEO.
Coverage (5)
- Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped BioSpace · 10h ago
- Sanofi nixes Kymab-originated OX40L antibody in eczema Endpoints News · 10h ago
- Sanofi shelves amlitelimab in atopic dermatitis after pipeline review FirstWord Pharma · 10h ago
- Sanofi to Drop Eczema Drug Amid Review of Pipeline Under New CEO WSJ · 10h ago
- Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout Fierce Biotech · 10h ago
Topics
Related trends
Trump Live Updates: FDA Peptide Meetings, Tariffs and Latest News
FDA advisory panels are currently debating the regulatory path and clinical viability of peptides following efforts to increase access to the controversial drugs.
FDA panel considers easing peptide restrictions
An FDA advisory panel is reviewing the loosening of restrictions on controversial peptides promoted by wellness influencers and RFK Jr.
Trump’s 100% Generic Drug Duty Threatens US Low-Cost Supply
Donald Trump has announced 100% tariffs on imported generic pharmaceutical drugs, sparking concerns over U.S. low-cost medical supplies.
Trump Sets 100% Tariff on Generic Drugs With Two-Year Delay
President Trump has announced new tariffs on generic drugs, sparking concerns over patient access and pharmaceutical industry responses.
Trump plans steep tariffs on generic drugs starting in 2028 to spur U.S. production
Donald Trump has announced plans to impose steep tariffs on generic drugs starting in 2028 to incentivize domestic U.S. production.
Novo sues Lilly, claiming misleading ads in weight-loss drug battle
Novo Nordisk has filed a lawsuit against Eli Lilly, alleging the rival company used false and misleading advertising regarding weight-loss drug efficacy.